Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12CNT | ISIN: SE0003656834 | Ticker-Symbol: M02
Stuttgart
06.06.25 | 10:50
0,013 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IZAFE GROUP AB Chart 1 Jahr
5-Tage-Chart
IZAFE GROUP AB 5-Tage-Chart
ACCESS Newswire
179 Leser
Artikel bewerten:
(1)

iZafe Group: Dosell Reaches 1,000 Units in Operation - Celebrates Milestone with Investor Event in Stockholm

STOCKHOLM, SWEDEN / ACCESS Newswire / June 3, 2025 / iZafe Group (STO:IZAFE-B) ("iZafe" or "the Company") today announces that its subsidiary Dosell has reached a significant milestone: more than 1,000 active Dosell units are now in use across Europe. This marks a clear breakthrough for safe and digital medication management in the home.

To celebrate this achievement, the company invites shareholders, partners, healthcare professionals and other stakeholders to an exclusive event at its Stockholm office on June 12.

"This milestone is both personal and strategic. Reaching 1,000 Dosell units in operation proves that we've made it through the most challenging phase - building a stable, scalable and in-demand solution. Now we're ready to grow in earnest. None of this would have been possible without the tremendous dedication of our team, our partners, and our shareholders who believed in us every step of the way. I look forward to sharing the next chapter with you," says Anders Segerström, CEO of iZafe Group.

During the evening, we will share the journey toward reaching 1,000 active Dosell units - the challenges we've faced, the key turning points, and why this moment represents a breakthrough for both our company and the digital healthcare sector.

You'll also get a glimpse of what's coming next - our strategic goals, technical roadmap, and how we plan to scale up the business both in Sweden and internationally.

Food and drinks will be served in a relaxed setting where you'll have the opportunity to connect with the Dosell team, fellow shareholders, healthcare innovators, and industry professionals.

Event Details:

  • Date: Wednesday, June 12

  • Time: From 6:00 PM

  • Location: iZafe Group HQ, David Bagares Gata 3A, Stockholm

  • Registration: https://forms.office.com/e/8qHzwLu5S8

Please note that registration is required and space is limited - spots will be allocated on a first-come, first-served basis.

About Dosell
Dosell is a medical technology solution that ensures the right person takes the right medication at the right time. The product is specifically designed to prevent double dosing and improve adherence - one of the greatest challenges in modern healthcare. Dosell is currently used by municipalities, private care providers and partners across Europe.

Contacts

Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm

E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company's Certified Adviser is DNB Carnegie Investment Bank AB. Further information is available at www.izafegroup.com

Image Attachments

Dosell 1000

Attachments

Dosell Reaches 1,000 Units in Operation - Celebrates Milestone with Investor Event in Stockholm

SOURCE: iZafe Group



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/dosell-reaches-1-000-units-in-operation-celebrates-milestone-with-inv-1034911

© 2025 ACCESS Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.